Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2015
Filed with the SEC on Feb 24, 2016 and accepted by EDGAR at Feb 24, 2016, 18:37 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2015-01-01 to 2015-12-31 | $11.41bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months2015-01-01 to 2015-12-31 | $5.33bn | us-gaap:GrossProfit |
| Research and development | 12 months2015-01-01 to 2015-12-31 | $140.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2015-01-01 to 2015-12-31 | $2.90bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2015-01-01 to 2015-12-31 | $2.33bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2015-01-01 to 2015-12-31 | $508.0m | us-gaap:InterestExpense |
| Income tax | 12 months2015-01-01 to 2015-12-31 | $622.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2015-01-01 to 2015-12-31 | $1.03bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | $3.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2015-01-01 to 2015-12-31 | $3.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2015-01-01 to 2015-12-31 | 304,920,035 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | $1.96bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $952.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2015-01-01 to 2015-12-31 | −$263.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2015-12-31 | $549.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $6.98bn | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $25.53bn | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $4.19bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-12-31 | $14.01bn | us-gaap:Liabilities |
| Long-term debt | At period end2015-12-31 | $7.85bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2015-12-31 | $128.3m | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2015-12-31 | $109.3m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2015-12-31 | $9.89bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2015-12-31 | 305,314,120 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001047469-16-010364. Last ingested by Listed: Oct 24, 2026, 15:11 ET. Listed shows no prices and gives no investment advice.